Search

everythinglearnresearchcommunity

for

Search:↓

Riboflavin 5′-phosphate (FMN) shows potential for treating androgen-related conditions but may be limited in treating prostate cancer.

RU58841, a substance from France, can potentially block the effects of hormones that cause hair loss and excessive hair growth, performing better than a similar substance, cyproterone acetate.

Tamoxifen may cause female hair loss by increasing androgen receptor expression.

Oral minoxidil may have more cardiovascular risks than topical minoxidil.

Ruxolitinib effectively and safely regrows hair in alopecia patients.

Oral 5-alpha reductase inhibitors do not increase breast cancer or benign breast disorder risk in women.

Exemestane may protect bones by stimulating osteoblast growth through androgen-related pathways.

Long-term treatment with palbociclib plus letrozole maintains quality of life in certain breast cancer patients.

Aromatase inhibitors can cause various adverse reactions, so monitoring is crucial.

Ritlecitinib effectively treats alopecia areata with manageable side effects.

Ro 10-9359 is an effective treatment for severe psoriasis but can cause side effects.

New drugs face challenges due to limited evidence, and safety updates are advised for some existing medications.

Bicalutamide, a drug with a good safety profile, is a promising new treatment for female pattern hair loss.

Red clover extract improved hair, skin, mood, sleep, and tiredness in postmenopausal women.

Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.

Testosterone reduces knee flexibility by affecting relaxin receptors.

Nandrolone and oxandrolone could help treat male health issues like muscle loss and low testosterone.

Finasteride increased hair count and regrowth in men with hair loss but also caused more sexual side effects than placebo.

Spanlastic formulations improve rivaroxaban's oral anticoagulation efficiency.